Trial Profile
A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Iodixanol (Primary) ; Iopamidol
- Indications Peripheral arterial disorders
- Focus Diagnostic use
- Sponsors GE Healthcare
- 14 Apr 2014 New trial record
- 31 Mar 2014 Results were reported in a GE Healthcare media release and were presented at the 63rd Annual Scientific Session and Expo of the American College of Cardiology (ACC)